Total Payments
$1.4M
2024 Payments
$174,818
Companies
43
Transactions
2,015
Medicare Patients
2,788
Medicare Billing
$303,221
Payment Breakdown by Category
Other$716,102 (52.4%)
Consulting$393,152 (28.8%)
Travel$198,815 (14.5%)
Food & Beverage$59,367 (4.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $458,138 | 148 | 33.5% |
| Consulting Fee | $393,152 | 213 | 28.8% |
| Travel and Lodging | $198,815 | 693 | 14.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $123,000 | 43 | 9.0% |
| Honoraria | $122,364 | 75 | 8.9% |
| Food and Beverage | $59,367 | 831 | 4.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $8,800 | 5 | 0.6% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $3,800 | 2 | 0.3% |
| Unspecified | $0 | 5 | 0.0% |
Payments by Type
General
$1.4M
2,010 transactions
Ownership
$0
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Shire North American Group Inc | $216,467 | 488 | $0 (2019) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $159,965 | 171 | $0 (2024) |
| Johnson & Johnson Surgical Vision, Inc. | $147,948 | 188 | $0 (2022) |
| Bausch & Lomb Americas Inc. | $115,201 | 148 | $0 (2024) |
| Dompe US, Inc. | $99,805 | 136 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $82,237 | 103 | $0 (2023) |
| Oyster Point Pharma, Inc. | $80,597 | 121 | $0 (2024) |
| TISSUETECH, INC. | $71,257 | 118 | $0 (2021) |
| BIOTISSUE HOLDINGS INC. | $66,516 | 67 | $0 (2024) |
| Lumenis, Inc | $42,110 | 5 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $174,818 | 268 | Bausch & Lomb Americas Inc. ($71,055) |
| 2023 | $177,797 | 222 | Bausch & Lomb Americas Inc. ($41,842) |
| 2022 | $206,767 | 226 | Sun Pharmaceutical Industries Inc. ($57,954) |
| 2021 | $113,858 | 188 | Dompe US, Inc. ($31,346) |
| 2020 | $115,470 | 121 | Novartis Pharmaceuticals Corporation ($34,790) |
| 2019 | $199,599 | 245 | Johnson & Johnson Surgical Vision, Inc. ($39,543) |
| 2018 | $176,533 | 305 | Shire North American Group Inc ($87,439) |
| 2017 | $202,595 | 440 | Shire North American Group Inc ($93,621) |
All Payment Transactions
2,015 individual payment records from CMS Open Payments — Page 1 of 81
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Food and Beverage | In-kind items and services | $6.17 | General |
| Category: Ophthalmology | ||||||
| 12/23/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Travel and Lodging | Cash or cash equivalent | $32.00 | General |
| Category: Dry eyes | ||||||
| 12/23/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Travel and Lodging | Cash or cash equivalent | $20.80 | General |
| Category: Dry eyes | ||||||
| 12/23/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Travel and Lodging | Cash or cash equivalent | $20.77 | General |
| Category: Dry eyes | ||||||
| 12/23/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Travel and Lodging | Cash or cash equivalent | $8.00 | General |
| Category: Dry eyes | ||||||
| 12/23/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Food and Beverage | Cash or cash equivalent | $6.48 | General |
| Category: Dry eyes | ||||||
| 12/18/2024 | Tarsus Pharmaceuticals, Inc. | XDEMVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: DEMODEX BLEPHARITIS | ||||||
| 12/12/2024 | Tarsus Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 12/12/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Travel and Lodging | In-kind items and services | $685.70 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/12/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Travel and Lodging | In-kind items and services | $184.28 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/12/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Travel and Lodging | In-kind items and services | $80.00 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/12/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $77.87 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/10/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | In-kind items and services | $17.51 | General |
| 12/10/2024 | Tarsus Pharmaceuticals, Inc. | XDEMVY (Drug) | Food and Beverage | In-kind items and services | $6.01 | General |
| Category: DEMODEX BLEPHARITIS | ||||||
| 12/09/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Dry eyes | ||||||
| 12/09/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,625.00 | General |
| Category: Dry eyes | ||||||
| 12/05/2024 | Tarsus Pharmaceuticals, Inc. | XDEMVY (Drug) | Food and Beverage | In-kind items and services | $147.96 | General |
| Category: DEMODEX BLEPHARITIS | ||||||
| 12/04/2024 | ABBVIE INC. | DURYSTA (Drug) | Food and Beverage | In-kind items and services | $89.64 | General |
| Category: EYE CARE | ||||||
| 12/02/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $7.46 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Travel and Lodging | In-kind items and services | $745.95 | General |
| Category: Dry eyes | ||||||
| 11/21/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Travel and Lodging | In-kind items and services | $215.86 | General |
| Category: Dry eyes | ||||||
| 11/21/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Food and Beverage | In-kind items and services | $96.09 | General |
| Category: Dry eyes | ||||||
| 11/21/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Travel and Lodging | In-kind items and services | $30.00 | General |
| Category: Dry eyes | ||||||
| 11/20/2024 | ABBVIE INC. | DURYSTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,275.00 | General |
| Category: EYE CARE | ||||||
| 11/20/2024 | Alcon Vision LLC | Rocklatan (Drug) | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: Ophthalmology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 900 | 2,372 | $293,198 | $128,170 |
| 2022 | 6 | 705 | 1,625 | $171,336 | $78,337 |
| 2021 | 10 | 799 | 1,681 | $106,982 | $63,663 |
| 2020 | 5 | 384 | 1,206 | $58,289 | $33,051 |
Total Patients
2,788
Total Services
6,884
Medicare Billing
$303,221
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 277 | 658 | $115,150 | $62,198 | 54.0% |
| 65778 | Placement of amniotic membrane on eye surface for wound healing | Office | 2023 | 23 | 30 | $120,000 | $31,477 | 26.2% |
| 83861 | Microfluid analysis of tears | Office | 2023 | 250 | 788 | $19,700 | $17,231 | 87.5% |
| 83516 | Analysis of substance using immunoassay technique, multiple step method | Office | 2023 | 251 | 792 | $19,800 | $8,884 | 44.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 41 | 41 | $10,988 | $4,962 | 45.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 58 | 63 | $7,560 | $3,418 | 45.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 164 | 302 | $52,850 | $28,497 | 53.9% |
| 65778 | Placement of amniotic membrane on eye surface for wound healing | Office | 2022 | 12 | 15 | $60,000 | $16,540 | 27.6% |
| 83861 | Microfluid analysis of tears | Office | 2022 | 176 | 530 | $13,250 | $11,460 | 86.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 125 | 164 | $19,680 | $10,706 | 54.4% |
| 83516 | Analysis of substance using immunoassay technique, multiple step method | Office | 2022 | 186 | 572 | $14,300 | $6,387 | 44.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 42 | 42 | $11,256 | $4,748 | 42.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 193 | 337 | $38,790 | $22,957 | 59.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 99 | 136 | $23,783 | $14,269 | 60.0% |
| 83861 | Microfluid analysis of tears | Office | 2021 | 198 | 556 | $13,900 | $12,458 | 89.6% |
| 83516 | Analysis of substance using immunoassay technique, multiple step method | Office | 2021 | 208 | 546 | $13,650 | $6,272 | 46.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 16 | 16 | $4,288 | $1,998 | 46.6% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 16 | 18 | $3,204 | $1,702 | 53.1% |
| 92004 | Eye and medical examination for diagnosis and treatment, new patient, 1 or more visits | Office | 2021 | 13 | 13 | $2,782 | $1,560 | 56.1% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 29 | 30 | $1,890 | $1,294 | 68.5% |
| 92002 | Eye and medical examination for diagnosis and treatment, new patient | Office | 2021 | 13 | 13 | $1,495 | $705.80 | 47.2% |
| 92133 | Diagnostic imaging of optic nerve of eye | Office | 2021 | 14 | 16 | $3,200 | $447.38 | 14.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 106 | 283 | $29,715 | $15,214 | 51.2% |
| 83861 | Microfluid analysis of tears | Office | 2020 | 118 | 430 | $10,750 | $9,436 | 87.8% |
| 83516 | Analysis of substance using immunoassay technique | Office | 2020 | 117 | 448 | $11,200 | $5,047 | 45.1% |
About Dr. Douglas Devries, O.D
Dr. Douglas Devries, O.D is a Optometrist healthcare provider based in Sparks, Nevada. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1629037296.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Douglas Devries, O.D has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $174,818 received in 2024. These payments were reported across 2,015 transactions from 43 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($458,138).
As a Medicare-enrolled provider, Devries has provided services to 2,788 Medicare beneficiaries, totaling 6,884 services with total Medicare billing of $303,221. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Optometrist
- Location Sparks, NV
- Active Since 03/21/2006
- Last Updated 07/08/2007
- Taxonomy Code 152W00000X
- Entity Type Individual
- NPI Number 1629037296
Products in Payments
- XIIDRA (Drug) $307,574
- Cequa (Drug) $111,478
- OXERVATE (Drug) $96,778
- Tecnis 1-piece IOL (Device) $87,544
- TYRVAYA (Drug) $80,597
- Prokera (Device) $71,142
- MIEBO (Drug) $67,843
- CEQUA (Drug) $40,937
- OptiLight (Device) $33,247
- EYSUVIS (Drug) $28,303
- ILUX (Device) $23,290
- XDEMVY (Drug) $23,005
- TearScience Lipiflow System (Device) $22,846
- LOTEMAX SM (Drug) $15,645
- Zerviate (Drug) $13,661
- STAR S4 IR Excimer Laser system (Device) $9,898
- TEARCARE SYSTEM (Device) $9,722
- LOTEMAX GEL (Drug) $8,845
- TearCare (Device) $8,407
- TearLab Osmolarity System (Device) $8,303
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Optometrist Doctors in Sparks
Troy Humphreys, Od Faao, OD FAAO
Optometrist — Payments: $41,793
Optometrist $41,793
Dr. Mackenzie Macintyre, Od, OD
Optometrist — Payments: $6,996
Optometrist $6,996
Dr. Evan Pritchett, Od, OD
Optometrist — Payments: $3,518
Optometrist $3,518
Timothy Huntting, Od, OD
Optometrist — Payments: $3,425
Optometrist $3,425
Benjamin Cheung, Od, OD
Optometrist — Payments: $3,135
Optometrist $3,135
Dr. Umari Duffus, O.d, O.D
Optometrist — Payments: $1,899
Optometrist $1,899